Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atogepant Added to BOTOX for Chronic Migraine Prevention
NCT05216263Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atogepant in chronic migraine, sponsored by AbbVie Inc.. Started Mar 2022; status: completed.
02
Drugs
atogepant
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT05216263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05216263.